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Abstract Chronic obstructive pulmonary disease (COPD) is a condition characterized by progressive airflow limitation, 
which causes considerable morbidity and mortality worldwide.Yet the burden of COPD is poorly recognized, and the 
disease remains an inadequately managed health problem. Few studies have attempted to quantify the impact of the 
disease on patient health, the healthcare system and society as a whole.This provided the rationale for Confronting COPD 
in North America and Europe, the first large-scale international survey of the burden of COPD.This paper describes how 
quantitative measures of healthcare resource utilization and workplace productivity loss were derived from patient 
responses to the Confronting COPD survey, to investigate the country-specific impact of COPD on the healthcare system 
and societyThe aim of this analysis is to inform countries of the economic impact of the condition, and demonstrate the 
need for better COPD treatment to improve health and reduce the sizeable burden of this disease. 
0 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
condition characterized by progressive airflow limitation, 
and is an umbrella term including chronic bronchitis and 
emphysema.The single most important factor associated 
with the development of COPD is a long-term history of 
smoking behaviour (I). COPD causes considerable 
mortality, leading to an estimated 2.7 million deaths 
worldwide in the year 2000 (2).A global survey of the 
burden of disease ranked COPD as the sixth leading 
cause of death in 1990, with a predicted rise to third 
place by the year 2020 (3-I). COPD is the only disease 
among the leading causes of death that is increasing in 
prevalence (5-6). In addition to mortality, the morbidity 
associated with COPD places a significant burden on the 
patient, with debilitating symptoms and impaired quality 
of life (34,7-8).The economic burden of the disease is 
borne by the healthcare system, the patient and society, 
resulting from extensive primary and secondary 
healthcare resource use and lost productivity (9-l I). 
Yet the burden of COPD is poorly recognized, and the 
disease remains poorly understood and inadequately 
managed. Surprisingly little is known about the condition 
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beyond its clinical nature, population prevalence and 
mortality rate, and few studies have attempted to 
quantify the impact of the disease on patient health, the 
healthcare system and society as a whole.This provided 
the rationale for Confronting COPD in North America and 
Europe, the first large-scale international survey of the 
burden of COPD.Telephone interviews were completed 
with patients and physicians in eight countries, to collect 
information on symptom frequency and severity, quality 
of life impact, disease management, the use of healthcare 
resources and lost productivity. As reported in detail 
elsewhere, the survey confirmed the detrimental impact 
of COPD on patient health and quality of life (I 2-l 3). 
The survey also highlighted a strong need to improve 
recognition and knowledge of COPD among both 
patients and healthcare professionals, and demonstrated 
that COPD is, on the whole, being poorly managed with 
currently available treatments. 
Worldwide consensus guidelines have been devised 
for the management of COPD (I). These guidelines 
provide recommendations for the effective diagnosis and 
treatment of patients in primary and secondary care. 
However, improving COPD management necessitates 
raising the profile of the disease with healthcare decision 
makers worldwide (14). Lack of recognition means that 
COPD tends to receive healthcare funding at a level far 
below what would be expected, given the mortality and 
morbidity impact of the disease (15). To highlight the 
economic burden of COPD and to fill gaps in current 
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knowledge about the impact of this disease, a country- 
specific analysis of the costs associated with the disease 
was conducted using the Confronting COPD survey 
data.The aim of this analysis was to: 
l estimate the annual per patient cost of COPD to the 
healthcare system, based on data collected from 
patients on healthcare resource use, such as primary 
care visits, hospitalizations and medications; 
l calculate the annual per patient cost of COPD 
resulting from work loss in COPD patients and their 
caregivers; 
l estimate the annual societal cost (direct and indirect 
costs) of COPD per patient; 
l investigate the relationships between COPD-related 
direct, indirect and total societal costs and a number of 
patient variables such as gender, smoking status, 
disease severity, the presence of comorbidity, and 
educational level. 
This paper details the methodology of the health 
economic analysis of the Confronting COPD survey. An 
overview of the results and country-specific findings are 
reported and discussed in detail elsewhere (I 6-23). 
SURVEY DETAILS 
Confronting COPD in North America and Europe was a 
telephone interview survey carried out between 
2 August 2000 and 3 I January 200 I, in a sample of 3265 
patients and 905 physicians (625 primary care 
practitioners, and 280 respiratory specialists) from the 
U.S.A., Canada, France, Germany, Italy, the Netherlands, 
Spain and the U.K. (12). The patient samples for the 
survey were identified by systematically screening 
geographically stratified samples of 20 I 92 I households, 
using random digit dialling of telephone numbers. More 
than 94% of the households had at least one phone line 
in all countries except Germany (89.3%) (24). The 
criteria for inclusion of patients in the survey were: 
l at least 45 years of age; 
l smoking history of at least IO years; 
l previously diagnosed with COPD, emphysema or 
chronic bronchitis or chronic bronchitis defined by 
persistent coughing with phlegm or sputum from the 
chest for the last 2 years or more (I 2). 
Patients were questioned using an adaptation of the 
American Thoracic Society (ATS) questionnaire, a 
structured instrument previously validated for the 
measurement of asthma symptoms in the general 
population, with proven reliability when administered by 
telephone interview (25-26). For the purposes of this 
survey, additional questions were included to collect 
information on patient demographics, activity limitation 
due to COPD, healthcare contacts and the use of 
respiratory therapy. The Medical Research Council 
(MRC) scale was also added to the questionnaire, as a 
measure of the severity of COPD symptoms (27) 
(Table I). 
The English version of the completed patient 
questionnaire was translated and back-translated into 
Dutch, French, German, Italian and Spanish, before being 
administered to respondents in their first language (I 2). 
The questionnaire took each respondent approximately 
25 minutes to complete. 
In all countries except Germany, patient responses to 
the Confronting COPD survey were used to conduct an 
economic analysis of the country-specific burden of 
COPD.The analysis included an assessment of healthcare 
resource use, lost productivity and associated costs, as 
described in detail below. 
ASSESSING COPD-RELATED 
HEALTHCARE RESOURCE USE 
Patients included in the Confronting COPD survey were 
asked questions about their COPD-related hospitaliza- 
tions, emergency room visits, primary care consultations, 
treatment, and laboratory tests, for the I2-month period 
prior to the survey. Patient responses were used to 
derive quantitative measures of healthcare resource 
utilization, as summarized in Tables Z+.The assumptions 
used to convert patient responses into resource 
measures were discussed and agreed with key opinion 
leaders in each country participating in the survey. A 
wide range of measures was included to provide a 
detailed breakdown of the impact of COPD on primary 
and secondary care. 
Information on hospital contacts was taken directly 
from the survey. Data was collected on the number and 
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proportion of patients reporting hospitalization and 
emergency room (ER) visits, and the frequency/mean 
number per patient of reported inpatient stays or ER 
visits. To assess the frequency of health care contacts, 
respondents were asked to report how often they had 
seen a doctor about their condition, and to identify the 
medical speciality of the doctor seen most often 
(Table 2). The number of patients receiving prescribed 
medication for COPD was obtained directly from the 
survey. Each patient was asked to provide the names of 
all drugs taken in the past year. Medications were 
grouped into drug classes as shown inTable 3. Bupropion 
was included as a drug that may be used by some COPD 
patients as a smoking cessation aid. The survey also 
collected data on the number of patients taking 
antibiotics for respiratory infections, the number of 
influenza vaccinations received, and the use of home 
oxygen therapy in the past I2 months (Table 3). Finally, 
patients were asked to report whether their physician 
had arranged for any diagnostic tests or investigations to 
be conducted over the past I2 months, in relation to 
their respiratory condition (Table 4). 
MEASURING WORK LOSS DUET0 
COPD 
The Confronting COPD survey collected data on patient 
work loss due to COPD, as summarized in Table 5. As 
the survey did not collect specific information on 
retirement, it was assumed that patients who had 
reached the standard retirement age in each country 
were no longer working (see the papers of each 
individual country for further information). 
CALCULATING THE COST IMPACT 
OF COPD 
The findings of the Confronting COPD survey were used 
to analyse the economic burden of COPD on the 
healthcare system and society by using local country- 
specific costs. All costs were calculated in the local 
currency and US dollars, with the U.K. cost results also 
calculated in Euros. The economic analysis included 
direct costs (resulting from contacts with healthcare 
professionals, inpatient hospitalizations, emergency room 
visits, treatment and laboratory tests for COPD) and 
indirect costs (resulting from work loss in patients with 
COPD), to estimate the total societal cost of COPD per 
patient. 
Direct costs 
In each country, annual per patient costs of COPD were 
calculated for each healthcare resource measure, by 
multiplying the mean frequency of use by unit costs 
derived by local health economics experts in each 
country participating in the economic analysis (Table 6). 
These costs were summed to provide an estimate of the 
mean direct cost of COPD per patient. 
Indirect and total societal costs 
To assess indirect costs, unit costs of a day lost from 
work were adjusted for age group (45-54 years, 
55-64years) and gender. The indirect costs of COPD 
were calculated by multiplying the mean number of days 
lost per patient by a unit cost for a day of lost 
productivity (caregiver work loss was not included in the 
indirect costs analysis). In the U.K., the U.S.A., Canada, 
France, Italy, and Spain, work loss was assessed using the 
human capital approach, whereby economic costs are 
calculated for the period from the start of illness-related 
work absence until the patient returns to work, or 
retires.The unit cost per day of work loss included both 
hourly wages and fringe benefits. In the Netherlands, 
indirect costs were calculated using the friction cost 
approach, as preferred by local health economists (29). 
This method reduces the possibility of overestimating 
productivity losses, by assuming that a patient missing 
work due to a long period of illness is likely to be 
replaced by another employee, rather than the position 
remaining vacant until the patient is able to return to 
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work.A maximum productivity loss value for the average 
time a position remains vacant during a period of patient 
illness may be ascertained by interviewing employers, or 
estimated from job centre statistics or government 
labour reports. However, outside the Netherlands, the 
friction cost approach remains controversial and is not 
generally used. 
Societal costs 
In each country, the annual direct and indirect cost 
results were summed to give an estimate of the mean 
per patient societal cost of COPD for the survey sample. 
Sub-analysis of cost results 
The direct, indirect and societal costs of COPD were 
examined further in relation to the following patient 
variables: 
l self-perceived severity of COPD; 
l severity of COPD according to score on the MRC 
Dyspnoea Scale (30) (mild: O-2, moderate: 3-4, 
severe: 5) (25,28); 
l gender; 
l smoking status; 
l presence of comorbidities; 
l education level (educated/no education beyond basic 
schooling). 
The aim of this analysis was to identify groups of 
patients in which the burden of COPD was dispro- 
portionately high. 
Once all the data for the economic analysis had been 
collected, information on healthcare resource use, time 
lost from work, and the direct, indirect and societal costs 
resulting from COPD were assessed separately for each 
country participating in the economic analysis of the 
Confronting COPD survey. The aim was to provide 
healthcare decision makers in each country with an 
analysis of the burden of COPD within a typical patient 
population, with broader consideration of local issues 
such as the effectiveness of current management 
strategies. In this way, it was anticipated that the data 
would help to demonstrate the need for the improved 
management of patients with COPD. 
DISCUSSION 
The economic analysis of Confronting COPD in North 
America and Europe used patient responses to a 
telephone interview to derive quantitative measures of 
healthcare resource use and work loss, which were used 
to estimate the direct and indirect costs of the disease. 
The survey included patients with a diagnosis of COPD, 
chronic bronchitis or emphysema, and patients who 
remained undiagnosed despite reporting symptoms of 
chronic bronchitis. 
RESPIRATORY MEDICINE 
The survey used randomized digit dialling and stratified 
sampling methods to obtain a national sample of patients 
with COPD from the general population. The vast 
majority of households in each country had at least one 
telephone line, so population coverage was high. While 
small numbers of patients without a telephone (most 
likely those of low socioeconomic status) would be 
missed by this sampling method, alternative survey 
methods may be more likely to exclude a significant 
proportion of patients with COPD. For example, the 
selection of patients using primary care practice 
registers would omit patients who have symptoms of 
COPD, but remain undiagnosed, which could be as many 
as three-quarters of patients with this disease (31). 
Alternative methods of selecting COPD patients for 
surveys may include specialist referral or lung function 
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criteria, both of which may result in the inclusion of 
disproportionately high numbers of patients with 
relatively severe disease. 
The survey relied on self-report to identify patients 
with a diagnosis of COPD, chronic bronchitis or 
emphysema. All patients included in the survey were 
aged 45 years or older, and 99.5% of patients were 
current or former smokers, with at least a IO pack-year 
smoking history, under the rationale that COPD 
develops in middle-age, most commonly following a long- 
term history of smoking behaviour. Patients who 
reported a diagnosis of asthma were excluded from 
taking part in the survey. It is possible that some of the 
patients who reported a diagnosis of COPD may also 
have had asthma, particularly as the use of spirometry to 
diagnose and differentiate COPD from other respiratory 
conditions is underutilized by primary care practitioners 
in many countries (I 2), though this would also apply if 
patients were recruited through practice databases. The 
inclusion of patients with COPD, rather than asthma, in 
this survey is supported by differences between the 
clinical results of the patient questionnaire (in terms of 
symptoms and disability levels) compared with those of 
an international asthma survey conducted using similar 
methodology (I 2,32). 
Patients with undiagnosed COPD were also included 
in the current survey.To reduce the possibility that these 
patients were suffering from other respiratory 
conditions, they had to meet strict symptom criteria 
(persistent cough with the production of phlegm or 
sputum from the chest for at least 2years) consistent 
with chronic bronchitis, as defined in international 
treatment guidelines for COPD. 
Patient responses to the Confronting COPD survey 
were used to quantify the extent of healthcare resource 
utilization, including contacts with healthcare 
professionals, inpatient hospitalizations, emergency room 
visits, treatment and laboratory tests, during the 
IZmonth period prior to the survey. A number of 
assumptions were agreed with local key opinion leaders 
for the data analysis, to ensure that the interpretation of 
patient responses reflected patterns of resource use that 
are observed in practice. For example, it was assumed 
that patients reporting the use of medication in more 
than one class would be using both drugs concurrently, 
and that patients would only receive one influenza 
vaccination during the course of a year. Overall, the 
direct costs calculated from the survey data are likely to 
represent conservative estimates, as some aspects of 
care that are typical in patients with COPD, such as 
pulmonary rehabilitation services, or home visits by 
healthcare professionals, were not included in the patient 
questionnaire. 
The indirect costs of COPD in the survey were 
calculated as the sum of the days absent from work in 
patients able to work, and the number of days lost in 
patients who were prevented from working at all during 
the previous year. This calculation is likely to 
underestimate the indirect cost of the disease, as time 
lost from work by the caregivers of patients with COPD 
was not included in the analysis. In addition, the survey 
was unable to assess social security/benefit costs arising 
from the illness and disability caused by COPD, which 
have been shown to have a significant impact on the 
economy in previous studies (33-35). Therefore, the 
Confronting COPD survey probably provides a 
conservative estimate of the annual per patient cost of 
COPD to society. 
The survey provided data on the prevalence rate of 
COPD in the population over the age of 45 years, which 
was estimated at around 4% for all participating 
countries, ranging from 3.2% in France to 5.4% in the 
Netherlands. However, as might be expected, these 
estimates tended to be higher than those previously 
reported in the individual countries (I 6-23), probably as 
a result of the inclusion of undiagnosed patients, and the 
methodology used to identify patients with the disease in 
this survey (e.g. self-report rather than patient 
databases).Although it could be interesting to apply the 
per patient costs to non-survey estimates of the number 
of patients with COPD in each country, this was not 
included in the results of the Confronting COPD 
analysis, because the inclusion of undiagnosed patients in 
this survey may invalidate comparisons with other 
estimates of the total societal burden of the disease. 
CONCLUSION 
This paper describes the methodology behind the 
economic analysis of Confronting COPD in North 
America and Europe. Quantitative measures of 
healthcare resource use and lost productivity were 
derived from patient responses to the survey, and used 
to calculate the direct and indirect costs of COPD in 
seven individual countries. It is anticipated that the 
results will be useful in informing individual countries of 
the societal impact of COPD, and raising awareness of 
the need for improved management. 
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